Terms: = Ovarian cancer AND PSA
200 results:
1. Cost-effectiveness analysis of olaparib maintenance therapy for BRCA mutation ovarian cancer in the public sector in Malaysia.
Yong CM; Yehgambaram PAP; Lee SWH
PLoS One; 2024; 19(2):e0298130. PubMed ID: 38300930
[TBL] [Abstract] [Full Text] [Related]
2. Latin America and the Caribbean Code Against cancer 1st Edition: Medical interventions including hormone replacement therapy and cancer screening.
Baena A; Paolino M; Villarreal-Garza C; Torres G; Delgado L; Ruiz R; Canelo-Aybar C; Song Y; Feliu A; Maza M; Jeronimo J; Espina C; Almonte M
Cancer Epidemiol; 2023 Oct; 86 Suppl 1():102446. PubMed ID: 37852728
[TBL] [Abstract] [Full Text] [Related]
3. Free psa and Clinically Significant and Fatal Prostate cancer in the PLCO Screening Trial.
Yim K; Ma C; Carlsson S; Lilja H; Mucci L; Penney K; Kibel AS; Eggener S; Preston MA
J Urol; 2023 Oct; 210(4):630-638. PubMed ID: 37384841
[TBL] [Abstract] [Full Text] [Related]
4. A Phase Ib, Open-label Study Evaluating the Safety and Efficacy of Ipatasertib plus Rucaparib in Patients with Metastatic Castration-resistant Prostate cancer.
Pook D; Geynisman DM; Carles J; de Braud F; Joshua AM; Pérez-Gracia JL; Llácer Pérez C; Shin SJ; Fang B; Barve M; Maruzzo M; Bracarda S; Kim M; Kerloeguen Y; Gallo JD; Maund SL; Harris A; Huang KC; Poon V; Sutaria DS; Gurney H
Clin Cancer Res; 2023 Sep; 29(17):3292-3300. PubMed ID: 37339186
[TBL] [Abstract] [Full Text] [Related]
5. Cost-effectiveness analysis of ovarian function preservation with GnRH agonist during chemotherapy in premenopausal women with early breast cancer.
Huang Y; Huang X; Huang X; Lin S; Luo S; Gu D; Weng X; Xu X
Hum Reprod; 2023 Jun; 38(6):1099-1110. PubMed ID: 37075316
[TBL] [Abstract] [Full Text] [Related]
6. Molecularly Imprinted Polymers for the Determination of cancer Biomarkers.
Pilvenyte G; Ratautaite V; Boguzaite R; Ramanavicius A; Viter R; Ramanavicius S
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835517
[TBL] [Abstract] [Full Text] [Related]
7. Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors: The JAVELIN PARP Medley Nonrandomized Controlled Trial.
Yap TA; Bardia A; Dvorkin M; Galsky MD; Beck JT; Wise DR; Karyakin O; Rubovszky G; Kislov N; Rohrberg K; Joy AA; Telli ML; Schram AM; Conte U; Chappey C; Stewart R; Stypinski D; Michelon E; Cesari R; Konstantinopoulos PA
JAMA Oncol; 2023 Jan; 9(1):40-50. PubMed ID: 36394849
[TBL] [Abstract] [Full Text] [Related]
8. Prediction of future risk of any and higher-grade prostate cancer based on the PLCO and SELECT trials.
Gelfond JA; Hernandez B; Goros M; Ibrahim JG; Chen MH; Sun W; Leach RJ; Kattan MW; Thompson IM; Ankerst DP; Liss M
BMC Urol; 2022 Mar; 22(1):45. PubMed ID: 35351104
[TBL] [Abstract] [Full Text] [Related]
9. Olaparib as first line in BRCA-mutated advanced ovarian carcinoma: Is it cost-effective in Spain?
Moya-Alarcón C; González-Domínguez A; Ivanova-Markova Y; Gimeno-Ballester V; Barretina-Ginesta MP; Pérez-Fidalgo JA; Redondo A
Gynecol Oncol; 2022 Feb; 164(2):406-414. PubMed ID: 34844775
[TBL] [Abstract] [Full Text] [Related]
10. Gut Microbiome-Dependent Metabolic Pathways and Risk of Lethal Prostate cancer: Prospective Analysis of a PLCO cancer Screening Trial Cohort.
Reichard CA; Naelitz BD; Wang Z; Jia X; Li J; Stampfer MJ; Klein EA; Hazen SL; Sharifi N
Cancer Epidemiol Biomarkers Prev; 2022 Jan; 31(1):192-199. PubMed ID: 34711629
[TBL] [Abstract] [Full Text] [Related]
11. Prostatic tissue: an unexpected finding in a mature ovarian teratoma : Case report and systematic literature review.
Pecorella I; Framarino Dei Malatesta ML; Riganelli L; Ciardi G; Porpora MG
Arch Gynecol Obstet; 2022 Apr; 305(4):969-976. PubMed ID: 34618214
[TBL] [Abstract] [Full Text] [Related]
12. Prostate cancer Incidence and Mortality Following a Negative Biopsy in a Population Undergoing psa Screening.
Pierre-Victor D; Parnes HL; Andriole GL; Pinsky PF
Urology; 2021 Sep; 155():62-69. PubMed ID: 34186135
[TBL] [Abstract] [Full Text] [Related]
13. Optimizing Nanopore sequencing-based detection of structural variants enables individualized circulating tumor DNA-based disease monitoring in cancer patients.
Valle-Inclan JE; Stangl C; de Jong AC; van Dessel LF; van Roosmalen MJ; Helmijr JCA; Renkens I; Janssen R; de Blank S; de Witte CJ; Martens JWM; Jansen MPHM; Lolkema MP; Kloosterman WP
Genome Med; 2021 May; 13(1):86. PubMed ID: 34006333
[TBL] [Abstract] [Full Text] [Related]
14. Body size throughout the life-course and incident benign prostatic hyperplasia-related outcomes and nocturia.
Khan S; Wolin KY; Pakpahan R; Grubb RL; Colditz GA; Ragard L; Mabie J; Breyer BN; Andriole GL; Sutcliffe S
BMC Urol; 2021 Mar; 21(1):47. PubMed ID: 33773592
[TBL] [Abstract] [Full Text] [Related]
15. Cost-effectiveness of olaparib versus routine surveillance in the maintenance setting for patients with
Tan DS; Chan JJ; Hettle R; Ghosh W; Viswambaram A; Yu CC
J Gynecol Oncol; 2021 Mar; 32(2):e27. PubMed ID: 33559410
[TBL] [Abstract] [Full Text] [Related]
16. Cost-effectiveness of laparoscopic disease assessment in patients with newly diagnosed advanced ovarian cancer.
Harrison RF; Cantor SB; Sun CC; Villanueva M; Westin SN; Fleming ND; Toumazis I; Sood AK; Lu KH; Meyer LA
Gynecol Oncol; 2021 Apr; 161(1):56-62. PubMed ID: 33536126
[TBL] [Abstract] [Full Text] [Related]
17. NKX3.1 expression in cervical 'adenoid basal cell carcinoma': another gynaecological lesion with prostatic differentiation?
Stewart CJR; Moses J
Pathology; 2021 Feb; 53(2):193-198. PubMed ID: 33032811
[TBL] [Abstract] [Full Text] [Related]
18. Identification of Plasma Glycosphingolipids as Potential Biomarkers for Prostate cancer (PCa) Status.
Snider AJ; Seeds MC; Johnstone L; Snider JM; Hallmark B; Dutta R; Moraga Franco C; Parks JS; Bensen JT; Broeckling CD; Mohler JL; Smith GJ; Fontham ETH; Lin HK; Bresette W; Sergeant S; Chilton FH
Biomolecules; 2020 Sep; 10(10):. PubMed ID: 33007922
[TBL] [Abstract] [Full Text] [Related]
19. Cost-effectiveness of olaparib as a maintenance treatment for women with newly diagnosed advanced ovarian cancer and BRCA1/2 mutations in the United States.
Muston D; Hettle R; Monberg M; McLaurin KK; Gao W; Swallow E; Zhang S; Kalemaj I; Signorovitch J; Moore K
Gynecol Oncol; 2020 Nov; 159(2):491-497. PubMed ID: 32951894
[TBL] [Abstract] [Full Text] [Related]
20. psa-based machine learning model improves prostate cancer risk stratification in a screening population.
Perera M; Mirchandani R; Papa N; Breemer G; Effeindzourou A; Smith L; Swindle P; Smith E
World J Urol; 2021 Jun; 39(6):1897-1902. PubMed ID: 32747980
[TBL] [Abstract] [Full Text] [Related]
[Next]
